Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Share:
Related EW
Earnings Scheduled For July 28, 2015
5 NYSE Healthcare Stocks With The Highest ROI
East West Petroleum Ends Fiscal Year 2015 With Record Revenues and Strong Financial Position (GuruFocus)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

Get Benzinga's Newsletters